Business

WeightWatchers Launches RxFlexFund™, a New Employer Model for Expanding GLP-1 Coverage

Provides a Differentiated Cost-Sharing Framework for GLP-1 Medications Paired With Clinical Oversight and Proven Behavior Change Support from WeightWatchers

articleWw International, Inc.October 17, 20253/company/ww-international-inc/news/weightwatchers-launches-rxflexfundtm-a-new-employer-model-for-expanding-glp-1-coverage
WeightWatchers Launches RxFlexFund™, a New Employer Model for Expanding GLP-1 Coverage

About this update from Ww International, Inc.

[{"type":"text","content":"Provides a Differentiated Cost-Sharing Framework for GLP-1 Medications Paired With Clinical Oversight and Proven Behavior Change Support from WeightWatchers Clinic\nNEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, today announced the launch of WeightWatchers RxFlexFund™, a first-of-its-kind solution that combines direct pricing from pharmaceutical manufacturers with flexible employer subsidy coverage for GLP-1s, integrated with WeightWatchers’ full-spectrum behavioral and clinical support. With WeightWatchers RxFlexFund, employers cover the cost of WeightWatchers Clinic and contribute a set percentage of medication costs, ranging from 25% to 75%, to help offset the impact of GLP-1 medication costs for their employees. Through this solution, employers also gain access to direct manufacturer pricing, providing transparent, competitive costs. Members of WeightWatchers RxFlexFund receive WeightWatchers’ holistic model of care, including access to FDA-approved GLP-1 medications under the care of obesity-trained clinicians, WeightWatchers’ wraparound behavior change program with nutritional support designed for those taking GLP-1s, and access to registered dietitians and fitness specialists. The ease of WeightWatchers Clinic means members receive prescriptions and refills, along with the support needed to increase adherence and minimize potential medication side effects to help maximize health outcomes. “Employers are at a crossroads when it comes to GLP-1 benefits,\" said Scott Honken, PharmD, Chief Commercial Officer of WeightWatchers. “Our clients consistently tell us that costs are rising and traditional coverage models leave little flexibility or opportunity for innovation. WeightWatchers RxFlexFund changes that by giving employers a clear, predictable way to offer GLP-1 access without navigating complex rebates or unpredictable add-on expenses. It opens the door to broader access while delivering meaningful clinical results and protecting the bottom line.” Annual healthcare expenses are reduced by 20% when individuals with at least one chronic condition are able to lose weight and move from having obesity to overweight.1 As noted in WeightWatchers for Business 2025 Annual Results Report, the WeightWatchers C...

More updates from Ww International, Inc.